| Company Name: | ONYX Pharmaceuticals Inc | | Ticker Symbol: | ONXX | | | WWW Address: | www.onyx-pharm.com | | CEO: | Dr. N. Anthony Coles, M.D. | | No. of Employees: | 197 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is engaged in the development of innovative therapies that target the molecular mechanisms that cause cancer.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 28.38 |  0.3 | 27.56 | 29.15 | 28.01 | 28.48 | 27.64 | 663925 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1,762.4 | 62.1 | 0.66 | 0.03 | 0.00 | 0.0 | 0.0 | 37.02 - 21.85 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 28.38 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 1,763.4 | mil |
| Latest Shares Outstanding | 62.1 | mil |
| Earnings pS (EPS) | 0.03 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 986,513 | $ |
| Effective Tax Rate | 15.1 | % |
| Float | 56.9 | mil |
| Float as % of Shares Outstanding | 99.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 24.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 50.10 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 26.1 | % |
| Pre-Tax Profit Margin | -2.0 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | -0.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -1.0 | % |
| Current Ratio | 37.7 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.19 | |
| LT Debt/Total Capital | 16.0 | % |
| Working Capital pS | 13.53 | $ |
| Cash pS | 5.39 | $ |
| Book-Value pS | 12.05 | $ |
| Tangible Book-Value pS | 12.05 | $ |
| Cash Flow pS | -0.10 | $ |
| Free Cash Flow pS | 0.10 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.36 | |
| Price/Tangible Book Ratio | 2.36 | |
| Price/Cash Flow | -297.7 | |
| Price/Free Cash Flow | 284.6 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.4 | 100 | 8,543 | 10,726 |
| 4 Weeks | 29.13 | 26.16 | 26.60 | 6.7 | 100 | 9,400 | 159,799 |
| 13 Weeks | 35.67 | 24.94 | 31.56 | -10.1 | 84 | 13,292 | 810,807 |
| 26 Weeks | 36.75 | 23.46 | 23.66 | 19.9 | 100 | 11,796 | 1,474,465 |
| 52 Weeks | 37.02 | 21.85 | 28.10 | 1.0 | 82 | 10,742 | 2,674,858 |
| YTD | 37.02 | 21.85 | - | -16.9 | 68 | 10,949 | 2,485,511 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 28.19 | 28.39 | 28.08 | 28.62 | 28.58 | 0.66 | 0.72 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 45.23 | NA | 52.22 |
| R&D | 28.86 | NA | 70.35 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | 0.0 |
| Earnings % | -32.6 | -32.8 | 0.0 |
| EPS % | -35.1 | -33.3 | 0.0 |
| EPS $ | -0.20 | -0.07 | 0.70 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 84.11 |
| Current Ratio | 13.9 |
| Quick Ratio (Acid Test) | 13.6 |
| Liquidity Ratio (Cash) | 12.56 |
| Receivables Turnover | 9.6 |
| Average Collection Period | 38 |
| Working Capital/Equity | 90.2 |
| Working Capital pS | 7.56 |
| Cash-Flow pS | 0.06 |
| Free Cash-Flow pS | -0.18 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 32.04 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 6.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.3 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.36 |
| Tobin's Q Ratio | 3.46 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -132.65 |
| Enterprise Value (EV)/Free Cash Flow | -154.01 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.36 |
| Price/Book Ratio - LTM | 2.36 |
| Price/Cash Flow Ratio | -297.7 |
| Price/Free Cash Flow Ratio - LTM | 284.6 |
| Price/Sales Ratio | 4.67 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 82.6 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.59 |
| Tangible Book Value pS - LTM | 12.05 |
| Book Value pS - LTM | 12.05 |
| Capital Invested pS | 7.65 |
| Cash pS - LTM | 5.39 |
| Cash Flow pS - LTM | -0.10 |
| Free Cash Flow pS - LTM | 0.10 |
| Earnings pS (EPS) | 0.03 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -5.14 |
| Free Cash Flow Margin 5YEAR AVG | -11,475.29 |
| Net Profit Margin | 1.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.41 |
| Return on Equity (ROE) | 0.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.41 |
| Return on Capital Invested (ROCI) | 0.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -17.4 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | 0.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -14.9 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 26.1 |
| EBIT Margin - LTM | -1.4 |
| Pre-Tax Profit Margin | 1.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 15.1 |
| Effective Tax Rate - 5YEAR AVRG. | 3.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 66 |
| Revenue per Employee | 986,513 |
| Net Income per Employee | 9,888 |
| Average Collection Period | 66 |
| Receivables Turnover | 9.6 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 0.05 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 0.45 |
| Fixed Assets Turnover | 4.07 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 0.83 |
| Revenue per $ Plant | 57.79 |
| Revenue per $ Common Equity | 0.41 |
| Revenue per $ Capital Invested | 0.41 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 41.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 125.2 |
| Research & Devlopment (R&D) as % of Revenue | 63.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 63.7 |
|
|  
|
| |
 |  |